### Abstract P39 Table 1

|                                | UDCA+BZF          | UDCA+OCA+BZF       | BZF
|--------------------------------|-------------------|--------------------|-----
| Median age starting BZF        | 53.5 (39-72)      | 60 (53-68)         | 66.5 (56-74)
| Median liver stiffness (Fibrosis score kPa) | 8.25 (3.3-46.2) | 10.5 (5.1-13.5)   | 12.8 (8.2-27.3)
| Total number of patients started on therapy | 14                | 5                  | 4   
| Co-existing liver disease      | 2 (14)            | 0 (0)              | 1 (25)
| Tried OCA for at least 12 months prior (%) | 8 (57)           | 5 (100)            | 0 (0)
| Total number of patients with >15% reduction in ALP (%) | 10 (71)          | 5 (100)            | 3 (75)
| Total number of patients with ALP>1xULN to ALP<1.67xULN (%) | 5 (36)           | 4 (80)             | 2 (50)
| Total number of patients with normalised ALP (%) | 2 (14)           | 1 (20)             | 1 (25)
| Median reduction in ALP between months 1-3 of starting BZF | 45.6 (7.5-72.9) | 52.9 (25.2-63.1)  | 27.2 (11.1-73.9)
| Total number of patients stopped therapy due to intolerance/side effects (%) | 2 (14)           | 0                  | 1 (25)

Ursodeoxycholic acid (UDCA) is first line therapy and Obeticholic acid (OCA) is second line therapy for those intolerant or unresponsive to UDCA. Bezafibrate (BZF) is an unlicensed therapy available for those intolerant or unresponsive to UDCA or OCA. The aim of this analysis is to investigate effectiveness and safety of BZF in a real world, specialist centre setting.

All patients dispensed BZF from July 2019 to June 2020 from Royal Free London Hospital were included. Using dispensing and clinical records, demographic, pharmacological and clinical data were collated.

24 patients were treated with BZF. 1 patient was excluded due to being treated with plasma exchange making her laboratory data uninterpretable. All patients were female with a median age of 56 years and as a group, had elevated median liver stiffness of 10.2kPa. The table 1 below shows the relevant outcomes. Biochemical response is presented in groups treated with BZF and UDCA, combination of BZF, OCA and UDCA or BZF alone.

Our data demonstrate that over a median of 2 months follow-up, BZF is well tolerated with only 3/23 (13%) stopping therapy. BZF was effective especially used as triple therapy, as shown by at least 15% reduction in ALP in 18/23 (78%) and ALP<1.67xULN in 15/23 (65%) even at this very early time point. No patients died or experienced complications of hepatic decompensation.

---

### P40 VIDEO CLINICS VERSUS STANDARD FACE-TO-FACE APPOINTMENTS FOR LIVER TRANSPLANT PATIENTS IN ROUTINE HOSPITAL CARE: A FEASIBILITY RANDOMISED CONTROLLED TRIAL OF MYVIDEOCLINIC

1Janet Jones*, 2Sarah Damer, 3Elaine O’Connell Francischetto, 4Richard Lifford, 3Kate Jolly, 2James Ferguson, 1Institute of Applied Health Research, University Of Birmingham, Birmingham, UK; 1National Institute for Health Research, Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK

10.1136/gutjnl-2020-BASL.50

**Introduction** There has recently been a rapid increase in the number of health and social care organisations offering remote consultations in order to minimise the spread of disease following the outbreak of COVID-19, but their effectiveness is unclear. The majority of studies focusing on remote consultations to date have evaluated telephone appointments. Although some studies have used video conferencing technology in the secondary care sector, the sample sizes have been small and they differ in their findings. This study evaluated the feasibility of implementing video clinics at a large hospital trust in the UK and assessed whether the intervention improved patient satisfaction compared to standard face-to-face appointments for liver transplant patients.

**Methods** Clinically stable liver transplant patients were randomised to video clinic appointments (intervention) or standard face-to-face appointments (usual care). The intervention group had routine follow-up appointments via secure video link. Participants were asked to complete post-appointment questionnaires over 12 months. The primary outcome was the difference in scores between baseline and study end by patient group for three domains of patient satisfaction using the Visit-Specific Satisfaction Instrument (VSQ-9). An embedded qualitative process evaluation used interviews to assess patient and staff experiences.

**Results** Fifty four patients were randomised: 29 to receive video clinics and 25 to usual care (recruitment rate 26.6%). Crossover from intervention to usual care was high (44.8%). 129 appointments were completed with 64% of questionnaires returned. Patient satisfaction (intention-to-treat analysis) increased in both intervention and usual care groups but the between-group difference was not significant after controlling for baseline scores. Video appointments were perceived to save patients time and money, and patients found video clinics to be less burdensome, with fewer negative impacts on their health. Technical problems with the software were common, however, the software is constantly evolving and as time goes on these types of problems should ease. Both clinicians and patients saw video clinic appointments as positive and beneficial.

**Discussion** The UK National Health Service is facing huge challenges with regards to staffing, budgets and space due to increasing patient numbers. Being innovative by using available technology to offer routine follow-up appointments via secure video link may help ease some of the burdens and free up clinic space for those patients who need to be seen face-to-face. This study outlines our experiences of using a remote video consultation system and the associated advantages and pitfalls.

---

### P41 IDENTIFYING ANTI-MITOCHONDRIAL ANTIBODY (AMA) POSITIVE PREVALENCE: AN UNDIAGNOSED DISEASE IN NORTH YORKSHIRE

Kayleigh Jones*, Charles Millson, John Hutchinson, Lucy Turner. York District Hospital, York, UK

10.1136/gutjnl-2020-BASL.51

**Introduction** Primary Biliary Cholangitis (PBC) is a chronic, progressive disorder, with a relatively well-tolerated treatment
A confident diagnosis of PBC relies upon a positive anti-mitochondrial antibody (AMA), a raised alkaline phosphatase (ALP) and/or immunoglobulin M (IgM). York Teaching Hospitals NHS Foundation Trust (YTHT) serves a population of 800,000, however our existing PBC database included only 100 patients. Given the prevalence (35 per 100,000) it is likely there are a significant number of undiagnosed cases within our population.

**Aim** To review historical positive AMA tests throughout YTHT, with the aim of identifying patients with hitherto undiagnosed PBC.

**Method** An IT-based search identified all positive AMA blood tests over a nine year period (2009–2018) (n = 731). An electronic note review of a proportion (n = 204) established demographic details, blood test results (including liver blood tests and immunoglobulins), the department requesting the test and consequential action taken.

**Results** Data from 2017–18 revealed 204 patients with a positive AMA, 88% of whom were female. Tests were predominantly requested by specialties other than hepatology; secondary care specialties (52%) GPs (38%) and hepatologists (9%). 34% had a known diagnosis of PBC. 31% of the cohort had a raised ALP (ALP >130 IU/L). Of those patients in whom immunoglobulins were performed (n = 112) over half, 57%, had a positive IgM. 115 patients (56%) had a positive AMA only, of these hepatology advice was sought in less than half (44%) of cases. 19 patients (9%) had results in keeping with a diagnosis of PBC, but were not referred, or previously known to, the hepatology service.

**Discussion** Our results have identified a significant number of patients in this population with undiagnosed PBC who could benefit from treatment. Identifying patients who potentially have established PBC is relatively non-invasive, and form part of the panel of blood tests frequently requested in primary and secondary care. As many such patients do not end up with either a formal diagnosis or appropriate referral, perhaps it is time to recommend all hospitals interrogate their laboratory databases in this way.

**REFERENCE**
1. www.yorkhospitals.nhs.uk/about-us/

---

**Abstract P42 Table 1**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Specialist review within 24 hours of admission</td>
<td>82.3%</td>
<td>92%</td>
</tr>
<tr>
<td>Diagnostic paracentesis</td>
<td>90.5%</td>
<td>92.9%</td>
</tr>
<tr>
<td>Antibiotics in patients with SBP</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Albumin in patients with SBP</td>
<td>70%</td>
<td>100%</td>
</tr>
<tr>
<td>Prophylactic antibiotics in variceal bleed</td>
<td>90.9%</td>
<td>95%</td>
</tr>
</tbody>
</table>